prikaz prve stranice dokumenta Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling
Biochemical and Biophysical Research Communications, 503 (2018), 2; 843-848. https://doi.org/10.1016/j.bbrc.2018.06.085
Klobučar, Marko; Grbčić, Petra; Pavelić, Sandra Kraljević; Jonjić, Nives; Visentin, Sarah; Sedić, Mirela

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Klobučar, M., Grbčić, P., Pavelić, S. K., Jonjić, N., Visentin, S. i Sedić, M. (2018). Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling. Biochemical and Biophysical Research Communications, 503. (2), 843-848. doi: 10.1016/j.bbrc.2018.06.085

Klobučar, Marko, et al. "Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling." Biochemical and Biophysical Research Communications, vol. 503, br. 2, 2018, str. 843-848. https://doi.org/10.1016/j.bbrc.2018.06.085

Klobučar, Marko, Petra Grbčić, Sandra Kraljević Pavelić, Nives Jonjić, Sarah Visentin i Mirela Sedić. "Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling." Biochemical and Biophysical Research Communications 503, br. 2 (2018): 843-848. https://doi.org/10.1016/j.bbrc.2018.06.085

Klobučar, M., et al. (2018) 'Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling', Biochemical and Biophysical Research Communications, 503(2), str. 843-848. doi: 10.1016/j.bbrc.2018.06.085

Klobučar M, Grbčić P, Pavelić SK, Jonjić N, Visentin S, Sedić M. Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling. Biochemical and Biophysical Research Communications [Internet]. 09.2018. [pristupljeno 06.11.2024.];503(2):843-848. doi: 10.1016/j.bbrc.2018.06.085

M. Klobučar, P. Grbčić, S. K. Pavelić, N. Jonjić, S. Visentin i M. Sedić, "Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling", Biochemical and Biophysical Research Communications, vol. 503, br. 2, str. 843-848, Rujan 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:385873. [Citirano: 06.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:385873
Podaci o radu
Naslov (engleski)Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling
AutorMarko Klobučar
AutorPetra Grbčić
AutorSandra Kraljević Pavelić
AutorNives Jonjić
AutorSarah Visentin
AutorMirela Sedić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za opću patologiju i patološku anatomiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patologija
Znanstveno / umjetničko
područje, polje i grana		BIOTEHNIČKE ZNANOSTI
Biotehnologija
Molekularna biotehnologija
Sažetak (engleski)
Acid ceramidase (ASAH1) has been implicated in the progression and chemoresistance in different cancers. Its role in colon cancer biology and response to standard chemotherapy has been poorly addressed so far. Here, we have investigated ASAH1 expression at the protein level in human colon cancer cell lines and tissues from colon cancer patients, and have examined in vitro the possible link between ASAH1 expression and functional activity of p53 protein whose inactivation is associated with the progression from adenoma to malignant tumour in colon cancer. Finally, we have explored the role of ASAH1 in response and resistance mechanisms to oxaliplatin (OXA) in HCT 116 colon cancer cells. We have demonstrated that human colon cancer cells and colorectal adenocarcinoma tissues constitutively express ASAH1, and that its expression is higher in tumour tissues than in normal colonic mucosa. Furthermore, we found an inverse correlation between ASAH1 expression and p53 functional activity. Obtained data revealed that ASAH1 was involved in HCT 116 cell response to OXA and that anti-proliferative, pro-apoptotic, anti-migratory and anti-clonogenic effects of OXA could be significantly increased by combination treatment with ASAH1 inhibitor carmofur. Increased OXA sensitivity was associated with downregulation of signalling involved in acquired resistance to OXA in colon cancer, in particular transglutaminase 2 and β1 integrin/FAK, which resulted in the suppression of NF-κB and Akt. Thus, combination of OXA with ASAH1 inhibitors could be a promising strategy to counter chemoresistance and improve treatment outcome in advanced colon cancer.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaBiochemical and Biophysical Research Communications
Brojčani podacivol. 503, br. 2, str. 843-848
p-ISSN0006-291X
DOIhttps://doi.org/10.1016/j.bbrc.2018.06.085
URN:NBNurn:nbn:hr:184:385873
Datum objave publikacije2018-09
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0006291X18313974
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-02-03 16:09:35